{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:12:44Z","timestamp":1789528364365,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02469-1","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T08:06:55Z","timestamp":1730534815000},"page":"547-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Romosozumab for the treatment of osteoporosis \u2013 a systematic review"],"prefix":"10.1007","volume":"48","author":[{"given":"V.-N.","family":"M\u00e4kinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"S\u00f8lling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"B. L.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"issue":"3","key":"2469_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S et al (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577\u2013589","journal-title":"Am J Hum Genet"},{"issue":"5\u20136","key":"2469_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1759720X18775936","volume":"10","author":"ASK S\u00f8lling","year":"2018","unstructured":"S\u00f8lling ASK, Harsl\u00f8f T, Langdahl B (2018) The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskel Dis 10(5\u20136):105\u2013115","journal-title":"Ther Adv Musculoskel Dis"},{"key":"2469_CR3","unstructured":"Krupa K, Parmar M, Delo LF (2023) Romosozumab. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC"},{"issue":"5","key":"2469_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"2469_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"2469_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26(1):19\u201326","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2469_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.239","volume":"54","author":"D Padhi","year":"2014","unstructured":"Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C et al (2014) Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 54(2):168\u2013178","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2469_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420","journal-title":"N Engl J Med"},{"issue":"1","key":"2469_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181\u2013187","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2469_CR10","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/jbmr.3176","volume":"32","author":"TM Keaveny","year":"2017","unstructured":"Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B et al (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32(9):1956\u20131962","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2469_CR11","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"2469_CR12","doi-asserted-by":"crossref","unstructured":"McClung M, Chines A, Brown J, Diez-Perez A, Resch H, Caminis J, et al (2014) Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. J Bone Mineral Res Wiley-Blackwell 111 river ST, hoboken 07030\u20135774, NJ USA","DOI":"10.1136\/annrheumdis-2015-eular.2291"},{"issue":"12","key":"2469_CR13","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30(12):2437\u20132448","journal-title":"Osteoporos Int"},{"key":"2469_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M et al (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"issue":"16","key":"2469_CR15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"8","key":"2469_CR16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C et al (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33(8):1407\u20131416","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2469_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A et al (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34(3):419\u2013428","journal-title":"J Bone Miner Res"},{"issue":"15","key":"2469_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"10102","key":"2469_CR19","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, Phase 3 trial. The Lancet 390(10102):1585\u20131594","journal-title":"The Lancet"},{"issue":"10","key":"2469_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1359\/jbmr.080506","volume":"23","author":"BM Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23(10):1591\u20131600","journal-title":"J Bone Miner Res"},{"key":"2469_CR21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae484","author":"MC Hartz","year":"2024","unstructured":"Hartz MC, Johannessen FB, Harsl\u00f8f T, Langdahl BL (2024) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae484","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2469_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3803\/EnM.2020.848","volume":"36","author":"KH Baek","year":"2021","unstructured":"Baek KH, Chung YS, Koh JM, Kim IJ, Kim KM, Min YK et al (2021) Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metabol (Seoul, Korea) 36(1):60\u201369","journal-title":"Endocrinol Metabol (Seoul, Korea)"},{"issue":"9","key":"2469_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3349\/ymj.2021.62.9.829","volume":"62","author":"K Inage","year":"2021","unstructured":"Inage K, Orita S, Eguchi Y, Shiga Y, Koda M, Aoki Y et al (2021) Time-course changes in bone metabolism markers and density in patients with osteoporosis treated with romosozumab: a multicenter retrospective study. Yonsei Med J 62(9):829\u2013835","journal-title":"Yonsei Med J"},{"key":"2469_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06889-2","author":"N Hong","year":"2023","unstructured":"Hong N, Shin S, Lee S, Rhee Y (2023) Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-023-06889-2","journal-title":"Osteoporos Int"},{"key":"2469_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S et al (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"issue":"5","key":"2469_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88(5):105219","journal-title":"Joint Bone Spine"},{"key":"2469_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","author":"T Kobayakawa","year":"2014","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J et al (2014) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep. https:\/\/doi.org\/10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"key":"2469_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91248-6","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y (2021) Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Scient Rep. https:\/\/doi.org\/10.1038\/s41598-021-91248-6","journal-title":"Scient Rep"},{"issue":"3","key":"2469_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","volume":"34","author":"M Kashii","year":"2023","unstructured":"Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34(3):563\u2013572","journal-title":"Osteoporos Int"},{"key":"2469_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10637","author":"H Inose","year":"2022","unstructured":"Inose H, Ariga A, Motoyoshi T, Fukushima K, Tomizawa S, Kato T et al (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study. JBMR Plus. https:\/\/doi.org\/10.1002\/jbm4.10637","journal-title":"JBMR Plus."},{"issue":"10","key":"2469_CR31","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32(10):1999\u20132009","journal-title":"Osteoporos Int"},{"issue":"9","key":"2469_CR32","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD et al (2018) A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2469_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","volume":"64","author":"PD Miller","year":"2014","unstructured":"Miller PD (2014) Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 64(2):290\u2013304","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2469_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2215\/CJN.11031017","volume":"13","author":"P Khairallah","year":"2018","unstructured":"Khairallah P, Nickolas TL (2018) Management of osteoporosis in CKD. Clin J Am Soc Nephrol 13(6):962\u2013969","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2469_CR35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39(6):1082\u20131090","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2469_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N et al (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112(1):34\u201344","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2469_CR37","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jbmr.4563","volume":"37","author":"PD Miller","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E et al (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res 37(8):1437\u20131445","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2469_CR38","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jcph.2050","volume":"62","author":"CP Hsu","year":"2022","unstructured":"Hsu CP, Maddox J, Block G, Bartley Y, Yu Z (2022) Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol 62(9):1132\u20131141","journal-title":"J Clin Pharmacol"},{"key":"2469_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1749-6632.2002.tb04204.x","volume":"966","author":"E Canalis","year":"2002","unstructured":"Canalis E, Delany AM (2002) Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 966:73\u201381","journal-title":"Ann N Y Acad Sci"},{"key":"2469_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.835720","volume":"13","author":"M Gado","year":"2022","unstructured":"Gado M, Baschant U, Hofbauer LC, Henneicke H (2022) Bad to the bone: the effects of therapeutic glucocorticoids on osteoblasts and osteocytes. Front Endocrinol (Lausanne) 13:835720","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2469_CR41","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1530\/EC-19-0104","volume":"8","author":"S Thiele","year":"2019","unstructured":"Thiele S, Hannemann A, Winzer M, Baschant U, Weidner H, Nauck M et al (2019) Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocr Connect 8(7):923\u2013934","journal-title":"Endocr Connect"},{"issue":"4","key":"2469_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-019-00649-3","volume":"106","author":"A Fassio","year":"2020","unstructured":"Fassio A, Adami G, Giollo A, Viapiana O, Malavolta N, Saviola G et al (2020) Acute effects of glucocorticoid treatment, tnf\u03b1 or il-6r blockade on bone turnover markers and wnt inhibitors in early rheumatoid arthritis: a pilot study. Calcif Tissue Int 106(4):371\u2013377","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2469_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.afos.2021.08.001","volume":"7","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Yano K, Ikari K, Okazaki K (2021) Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: an open-label, randomized, pilot study. Osteoporos Sarcopenia 7(3):110\u2013114","journal-title":"Osteoporos Sarcopenia"},{"issue":"3","key":"2469_CR44","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/mr\/roac059","volume":"33","author":"T Mochizuki","year":"2023","unstructured":"Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K (2023) Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: a randomized clinical pilot study. Mod Rheumatol 33(3):490\u2013495","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2469_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/mr\/roac014","volume":"33","author":"T Kobayakawa","year":"2023","unstructured":"Kobayakawa T, Miyazaki A, Kanayama Y, Hirano Y, Takahashi J, Suzuki T et al (2023) Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration. Mod Rheumatol 33(1):96\u2013103","journal-title":"Mod Rheumatol"},{"issue":"8","key":"2469_CR46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW et al (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am Vol 102(8):693\u2013702","journal-title":"J Bone Joint Surg Am Vol"},{"issue":"5","key":"2469_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jbmr.307","volume":"26","author":"MS Ominsky","year":"2011","unstructured":"Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M et al (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012\u20131021","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2469_CR48","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","volume":"102","author":"M Bhandari","year":"2020","unstructured":"Bhandari M, Schemitsch EH, Karachalios T, Sancheti P, Poolman RW, Caminis J et al (2020) Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture a randomized phase-2 study. J Bone Joint Surg 102(16):1416\u20131426","journal-title":"J Bone Joint Surg"},{"issue":"Suppl 1","key":"2469_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American Association of Clinical endocrinologists\/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1\u201346","journal-title":"Endocr Pract"},{"issue":"11","key":"2469_CR50","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","volume":"31","author":"MR McClung","year":"2020","unstructured":"McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J et al (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31(11):2231\u20132241","journal-title":"Osteoporos Int"},{"key":"2469_CR51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.yrtph.2016.08.010","volume":"81","author":"L Chouinard","year":"2016","unstructured":"Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J et al (2016) Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol 81:212\u2013222","journal-title":"Regul Toxicol Pharmacol"},{"key":"2469_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101635","volume":"17","author":"H Inose","year":"2022","unstructured":"Inose H, Kato T, Tomizawa S, Ariga A, Motoyoshi T, Fukushima K et al (2022) Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: a multicenter retrospective study. Bone Rep 17:101635","journal-title":"Bone Rep"},{"issue":"7","key":"2469_CR53","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1210\/clinem\/dgab193","volume":"106","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL, Hofbauer LC, Forfar JC (2021) Cardiovascular safety and sclerostin inhibition. J Clin Endocrinol Metab 106(7):1845\u20131853","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2469_CR54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.yexcr.2016.06.007","volume":"345","author":"T Cai","year":"2016","unstructured":"Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J et al (2016) WNT\/\u03b2-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res 345(2):206\u2013217","journal-title":"Exp Cell Res"},{"issue":"5","key":"2469_CR55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.17219\/acem\/169567","volume":"33","author":"P Koce\u0142ak","year":"2024","unstructured":"Koce\u0142ak P, Puzianowska-Ku\u017anicka M, Olszanecka-Glinianowicz M, Chudek J (2024) Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification. Adv Clin Exp Med 33(5):519\u2013532","journal-title":"Adv Clin Exp Med"},{"issue":"2","key":"2469_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11255-018-2033-4","volume":"51","author":"M Li","year":"2019","unstructured":"Li M, Zhou H, Yang M, Xing C (2019) Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol 51(2):311\u2013323","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2469_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2013.05.010","volume":"56","author":"G Hampson","year":"2013","unstructured":"Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56(1):42\u201347","journal-title":"Bone"},{"issue":"10","key":"2469_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033038","volume":"13","author":"F Burger","year":"2024","unstructured":"Burger F, Roth A, Mach F, Thouverey C, Ferrari SL, Miteva K (2024) Reduced sclerostin expression in human atherosclerotic plaques links to ischemic stroke. J Am Heart Assoc 13(10):e033038","journal-title":"J Am Heart Assoc"},{"key":"2469_CR59","unstructured":"Amgen I. Background Information for Bone, Reproductive and Urologic Drugs Advisory Committee https:\/\/public4.pagefreezer.com\/browse\/FDA\/04-03-2022T19:30\/https:\/\/www.fda.gov\/media\/121255\/download2019"},{"issue":"18","key":"2469_CR60","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809","journal-title":"N Engl J Med"},{"issue":"8","key":"2469_CR61","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"CW Sing","year":"2018","unstructured":"Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT et al (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33(8):1422\u20131434","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2469_CR62","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1210\/clinem\/dgaa481","volume":"105","author":"AJ Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez AJ, Ernst MT, Nybo M, Prieto-Alhambra D, Ebeling PR, Hermann AP et al (2020) Oral bisphosphonate use reduces cardiovascular events in a cohort of danish patients referred for bone mineral density. J Clin Endocrinol Metab. 105(10):3215\u20133225","journal-title":"J Clin Endocrinol Metab."},{"key":"2469_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.021","volume":"301","author":"M Casula","year":"2020","unstructured":"Casula M, Olmastroni E, Galimberti F, Tragni E, Corrao G, Scotti L et al (2020) Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: a population-based study. Atherosclerosis 301:1\u20137","journal-title":"Atherosclerosis"},{"issue":"6","key":"2469_CR64","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","volume":"31","author":"SR Cummings","year":"2020","unstructured":"Cummings SR, McCulloch C (2020) Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int 31(6):1019\u20131021","journal-title":"Osteoporos Int"},{"key":"2469_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104697","volume":"115","author":"JR Turk","year":"2020","unstructured":"Turk JR, Deaton AM, Yin J, Stolina M, Felx M, Boyd G et al (2020) Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol 115:104697","journal-title":"Regul Toxicol Pharmacol"},{"key":"2469_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH van Lierop","year":"2017","unstructured":"van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE (2017) Sclerostin deficiency in humans. Bone 96:51\u201362","journal-title":"Bone"},{"key":"2469_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, Cai X, Yang W, Gao L, Chen L, Wu J et al (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone 130:115121","journal-title":"Bone"},{"key":"2469_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6570","author":"J Bovijn","year":"2020","unstructured":"Bovijn J, Krebs K, Chen CY, Boxall R, Censin JC, Ferreira T et al (2020) Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aay6570","journal-title":"Sci Transl Med."},{"issue":"7","key":"2469_CR69","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jbmr.4287","volume":"36","author":"G Holdsworth","year":"2021","unstructured":"Holdsworth G, Staley JR, Hall P, van Koeverden I, Vangjeli C, Okoye R et al (2021) Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans. J Bone Miner Res 36(7):1326\u20131339","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2469_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.afos.2021.09.002","volume":"7","author":"Y Takeuchi","year":"2021","unstructured":"Takeuchi Y (2021) Romosozumab and cardiovascular safety in Japan. Osteoporos Sarcopenia 7(3):89\u201391","journal-title":"Osteoporos Sarcopenia"},{"issue":"8","key":"2469_CR71","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/jcm10081660","volume":"10","author":"A Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A, Faruque J, Vallejo-Yag\u00fce E, Weiler S, Winter EM, Burden AM (2021) Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the us Food and DRUG ADministration Adverse Event Reporting System (FAERS). J Clin Med. 10(8):1660","journal-title":"J Clin Med."},{"issue":"5","key":"2469_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126413","volume":"10","author":"S Matsuda","year":"2015","unstructured":"Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H et al (2015) Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One 10(5):e0126413","journal-title":"PLoS One"},{"issue":"3","key":"2469_CR73","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/jc.2012-3680","volume":"98","author":"EM Lewiecki","year":"2013","unstructured":"Lewiecki EM, Cummings SR, Cosman F (2013) Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 98(3):946\u2013953","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2469_CR74","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00198-020-05569-9","volume":"31","author":"T Thomas","year":"2020","unstructured":"Thomas T, Casado E, Geusens P, Lems WF, Timoshanko J, Taylor D et al (2020) Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts. Osteoporos Int 31(12):2303\u20132311","journal-title":"Osteoporos Int"},{"key":"2469_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.01.014","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.014","journal-title":"Endocr Pract"},{"key":"2469_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae119","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, De Beur SJ, Langdahl B et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Miner Res"},{"key":"2469_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/978-3-030-87950-1_18","volume-title":"New Horizons in Osteoporosis Management","author":"Y El Miedany","year":"2022","unstructured":"El Miedany Y, Bahlas S (2022) Treat-to-Target in Osteoporosis. In: El Miedany Y (ed) New Horizons in Osteoporosis Management. Springer International Publishing, Cham, pp 473\u2013489"},{"issue":"10","key":"2469_CR78","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","volume":"32","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L et al (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines\u202f: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32(10):1951\u20131960","journal-title":"Osteoporos Int"},{"issue":"1","key":"2469_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312","journal-title":"Osteoporos Int"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02469-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:47:38Z","timestamp":1740980858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02469-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2469"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02469-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VM: No conflicts of interests. ASS: Honoraria for lectures: Amgen, Gedeon-Richter. MM: Advisor: Amgen, UCB. Speaker: Amgen, Alexion. BL: Investigator and advisor; UCB, Amgen, Samsung-Bioepis, Angitia, Entera-Bio. Speaker; Amgen, UCB, Gedeon-Richter, Astra-Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This article does not contain any study with human participants and animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}